{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:46:50Z","timestamp":1768265210085,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatitis B virus (HBV) infection is a worldwide concern with a broad distribution. In immunosuppressed populations, such as solid organ and hematopoietic stem cell transplant (HSCT) recipients, it can reactivate leading to acute hepatic failure. Different risk factors are known for higher rates of reactivation, and entecavir, tenofovir, and lamivudine are often used for prophylaxis and treatment. However, data regarding the impact of antiviral drugs in neutrophil and platelet engraftment are still unknown and concern the management of viral hepatitis post\u2010HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a single\u2010center, retrospective, observational study reviewing medical records of patients referred for hematopoietic stem cell transplant from 2010 to 2017, which were also HBV infected, aiming to describe outcomes related to antiviral treatment and also the impact on platelet and neutrophil recovery after transplant. A secondary goal consisted of analyzing the impact of HBV infection in early and late mortality post\u2010HSCT. The study included patients with positive blood bank screening for hepatitis B infection (HBsAg, Anti\u2010HBc or HBV\u2010NAT), confirmed later on by a laboratory routine serology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1132 hematopoietic stem cell recipients were assessed between 2010 and 2017. Eighty\u2010six patients were confirmed to have HBV infection, of which six were HBsAg\u2010positive, 20 were isolated anti\u2010HBc\u2010positive, and 60 had resolved infection (anti\u2010HBc\u2010positive and anti\u2010HBs\u2010positive). With regard to prophylaxis, 19 patients underwent HSCT on HBV antiviral therapy or prophylaxis: two were HBeAg\u2010positive, three were HBeAg\u2010negative and HBV\u2010DNA was only detectable in three of them. Moreover, one patient had an occult HBV infection. Regarding therapy, 9 patients were on entecavir, 6 patients on lamivudine, two on tenofovir, and two of them on a combination of tenofovir\u00a0+\u00a0lamivudine due to HIV co\u2010infection. Reverse seroconversion was not identified in any patients receiving antiviral therapy or prophylaxis, but it was detected in one patient with occult hepatitis B and another with resolved infection. No severe side effects led to therapy discontinuation in the treated group, which also did not have any significant delay in neutrophil or platelet engraftment when compared to patients without antiviral therapy. In addition, the only factors associated with increased mortality were transplant onset after 50\u00a0years, allogeneic transplant and myeloablative conditioning regimens. Interestingly, the presence of HBsAg or detectable HBV\u2010DNA was not related to worse outcomes, neither the use of rituximab. In multivariate analysis, the use of antiviral therapy, the occurrence of graft\u2010versus\u2010host disease or CMV reactivation also was not linked to increased mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>To sum up, HBV serology, ALT, and HBV\u2010DNA monitoring are essential to detect hepatic flares earlier, even in populations with chronic inactive hepatitis, due to the possibility of later seroconversion. HBV infection was not related to increased 2\u2010year mortality post\u2010transplant. Antiviral prophylaxis did not cause any important clinical or laboratory side effects that could demand discontinuation, and its use was not associated with later neutrophil and platelet engraftments.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.13243","type":"journal-article","created":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T17:01:15Z","timestamp":1578157275000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-2353","authenticated-orcid":false,"given":"Bruno Fernando","family":"Buzo","sequence":"first","affiliation":[{"name":"Departamento de Mol\u00e9stias Infecciosas e Parasit\u00e1rias Hospital das Cl\u00ednicas HCFMUSP Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-9514","authenticated-orcid":false,"given":"J\u00e9ssica Fernandes","family":"Ramos","sequence":"additional","affiliation":[{"name":"Departamento de Mol\u00e9stias Infecciosas e Parasit\u00e1rias Hospital das Cl\u00ednicas HCFMUSP Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"},{"name":"Departamento de Hematologia Hemoterapia e Terapia Celular Hospital das Cl\u00ednicas HCFMUSP Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Ariza","family":"Marques Rossetti","sequence":"additional","affiliation":[{"name":"Departamento de Hematologia Hemoterapia e Terapia Celular Hospital das Cl\u00ednicas HCFMUSP Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanci","family":"Salles","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Pr\u00f3\u2010Sangue Hospital das Cl\u00ednicas HCFMUSP S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Mendrone\u2010J\u00fanior","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Pr\u00f3\u2010Sangue Hospital das Cl\u00ednicas HCFMUSP S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-619X","authenticated-orcid":false,"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[{"name":"Departamento de Hematologia Hemoterapia e Terapia Celular Hospital das Cl\u00ednicas HCFMUSP Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"},{"name":"Funda\u00e7\u00e3o Pr\u00f3\u2010Sangue Hospital das Cl\u00ednicas HCFMUSP S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-6156","authenticated-orcid":false,"given":"Ana Catharina","family":"de Seixas Santos Nastri","sequence":"additional","affiliation":[{"name":"Departamento de Mol\u00e9stias Infecciosas e Parasit\u00e1rias Hospital das Cl\u00ednicas HCFMUSP Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22945"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.10.007"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.116"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61412-X"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.7510"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.1"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00773-8"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.728"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.08.007"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704457"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1345722"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.328"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00678.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ344"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01313.x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.027"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1118"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.290"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.11.009"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2011.01409.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23644"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2010.05.001"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31824e3db4"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.12.041"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13187"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1214-5"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762012000300005"},{"issue":"1","key":"e_1_2_11_32_1","first-page":"21","article-title":"Boletim Epidemiol\u00f3gico \u2013 Hepatites Virais","volume":"1","author":"Pereira GFM","year":"2011","journal-title":"Bol Epidemiol\u00f3gico \u2013 Hepatites Virais"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.023"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.13243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:12:50Z","timestamp":1693818770000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.13243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/tid.13243"],"URL":"https:\/\/doi.org\/10.1111\/tid.13243","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"2019-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13243"}}